Claims for Patent: 9,663,762

Summary for Patent: 9,663,762

Title:	Methods for obtaining target cells
Abstract:	Methods for recovering target cells using degradable three dimensional matrices are described.
Inventor(s):	Coleman; Michael (Houston, TX), Vykoukal; Jody (Houston, TX)
Assignee:	Ingeneron, Inc. (Houston, TX)
Application Number:	13/896,246
Patent Claims:	1. A method for obtaining target cells from a fluid, cell-containing sample, the method comprising: a) providing a fluid, cell-containing sample; b) passing the sample through a degradable matrix filter mounted as an insert in a conical tube or filter unit, the filter having a three dimensional structure that is fabricated of an enzyme degradable biopolymer, wherein the matrix filter has a porosity that physically retains target cells based on a size of the target cells while allowing passage of smaller non-target cells, including erythrocytes, through the matrix filter; c) removing the filter from the conical tube or filter unit and recovering target cells retained within the matrix filter by enzymatically degrading said matrix filter such that at least 50% of the three dimensional structure of the matrix filter is enzymatically degraded such that the three dimensional structure is no longer able to physically retain the target cells; and d) recovering the target cells from the enzymatically degraded matrix filter by centrifugation. 2. The method of claim 1, wherein the fluid, cell-containing sample is peripheral blood, umbilical blood, bone marrow aspirate, lymph, cerebral spinal fluid, ductal fluid, needle biopsy aspirate, or lipoaspirate. 3. The method of claim 1, wherein the matrix comprises one or more of collagen, hyaluronic acid, laminin, chitosan, cellulose, alginate and products of each of collagen, hyaluronic acid, laminin, chitosan, cellulose, and alginate. 4. The method of claim 1, wherein degrading the matrix comprises contacting the matrix with a collagenase, hyaluronidase, or protease for an amount of time sufficient to digest at least 90% of the matrix filter. 5. The method of claim 1, wherein the matrix filter containing the physically trapped target cells is placed into culture to expand the cells prior to recovery of the cells by degrading the matrix. 6. The method of claim 1, wherein the matrix filter has at least one capture ligand attached to it prior to passing the sample through the matrix filter. 7. The method of claim 6, wherein at least one capture ligand is an antibody or an antigen binding fragment thereof has binding affinity for a cell surface molecule on the target cell. 8. The method of claim 7, wherein the cell surface molecule is epithelial cell adhesion molecule (EpCAM), mucin 1 (MUC1), Human Epidermal Growth Factor Receptor 2 (HER2), or Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP). 9. The method of claim 7, wherein the antibody or antigen binding fragment thereof has binding affinity for CD71, CD36, CD45, glycophorin A, CD35, CD47, Stage specific embryonic antigen-4 (SSEA-4), CD117, or CD146. 10. The method of claim 6, wherein at least one capture ligand is a lectin selected from the group consisting of soybean agglutinin (SBA), peanut agglutinin (PNA), Erythrina cristagalli lectin (ECL), Allomyrina dichotoma lectin (Allo A), Viscum album agglutinin (VAA), concanavalin A (Con A), Lens culinaris lectin (LcH), and Pisum sativum agglutin (PSA). 11. The method of claim 1, wherein the target cells are circulating tumor cells, disseminated tumor cells, embryonic cells, or fetal red blood cells. 12. The method of claim 1, wherein the fluid, cell-containing sample is a lipoaspirate.

Details for Patent 9,663,762

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2030-11-16
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2030-11-16
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2030-11-16
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2030-11-16
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2030-11-16
Aimmune Therapeutics, Inc.	PALFORZIA	peanut (arachis hypogaea) allergen powder	Powder	125696	01/31/2020		2030-11-16